WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, will announce its second quarter 2007 results on Wednesday, July 25, 2007 prior to the opening of the NASDAQ Stock Market, followed by a conference call at 10:00 a.m. ET. OXiGENE’s President and Chief Executive Officer, Dr. Richard Chin, Chief Scientific Officer, Dr. David Chaplin, Chief Business Officer, John Kollins and Chief Financial Officer, James Murphy, will host the call.
